ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,755Medicare Part D Prescriptions Filled, Including Refills

Rank: 74 out of 1571

$519K Total Retail Price of All Prescriptions

Rank: 210 out of 1571

242 Patients Receiving at Least One Drug in Part D
77%Patients 65 Years and Older
70% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 242 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

22% of this provider’s 242 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

1% of this provider’s 6,659 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $99 among peers.

Prescriptions per Patient

36 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
LEVOTHYROXINE SODIUM 330 264 1 6
SIMVASTATIN 314 243 2 1
HYDROCODONE-ACETAMINOPHEN 304 163 S3 3 3
GABAPENTIN 257 206 4 12
AMLODIPINE BESYLATE 244 201 5 2
FAMOTIDINE 208 142 6 54
OMEPRAZOLE 201 122 7 4
WARFARIN SODIUM 193 134 8 14
DONEPEZIL HCL 187 174 9 24
METFORMIN HCL 170 126 10 9
FUROSEMIDE 152 110 11 7
CLOPIDOGREL 145 109 12 21
NEXIUM 142 110 13 39
LOSARTAN POTASSIUM 133 128 14 17
HYDROCHLOROTHIAZIDE 125 107 15 18
PANTOPRAZOLE SODIUM 119 78 16 23
METOPROLOL TARTRATE 119 89 16 13
ZOLPIDEM TARTRATE 114 74 18 20
POTASSIUM CHLORIDE 107 88 19 27
KLOR-CON 8 101 87 20 152
ALLOPURINOL 100 100 21 36
METOPROLOL SUCCINATE 94 85 22 16
MELOXICAM 92 50 23 49
CARVEDILOL 90 56 24 10
NATEGLINIDE 89 71 25 225
ESCITALOPRAM OXALATE 86 79 26 104
LEVOFLOXACIN 81 56 27 79
LISINOPRIL 81 77 27 5
PLAVIX 80 66 29 28
RAMIPRIL 78 48 30 94
PRAVASTATIN SODIUM 77 75 31 26
TRAMADOL HCL 74 51 32 31
JANUVIA 73 45 33 50
CLONIDINE HCL 71 71 34 45
CYCLOBENZAPRINE HCL 67 20 R 35 195
ISOSORBIDE MONONITRATE ER 63 56 36 48
BENAZEPRIL HCL 61 41 37 32
ALENDRONATE SODIUM 60 49 38 22
DIOVAN 60 52 38 19
AZITHROMYCIN 59 48 40 58
SINGULAIR 54 32 41 88
SERTRALINE HCL 53 43 42 52
FENTANYL 51 40 S2 43 132
BACLOFEN 50 48 44 120
ENALAPRIL MALEATE 50 21 44 81
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 17, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.